» Articles » PMID: 21121231

Varicella Seroprevalence in the U.S.: Data from the National Health and Nutrition Examination Survey, 1999-2004

Overview
Publisher Sage Publications
Specialty Public Health
Date 2010 Dec 3
PMID 21121231
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: We estimated the varicella seroprevalence among the U.S. population aged 6-49 years based on retested National Health and Nutrition Examination Survey (NHANES) specimens collected between 1999 and 2004--originally tested using a method unsuitable for detecting vaccine-induced immunity--and compared it with historical estimates.

Methods: We performed a confirmatory test suitable for detecting vaccine-induced immunity on all available specimens from 6- to 19-year-olds who originally tested negative (n = 633), and on 297 randomly selected specimens that had tested positive. Retest results superseded original results for determining seroprevalence. We assessed seroprevalence for the entire sample aged 6-49 years (n = 16,050) by participant demographic characteristics and compared it with historical estimates (NHANES 1988-1994).

Results: The percentage of false-negative results for the original test was higher for specimens from younger children (6-11 years of age: 27.5%; 12-19 years of age: 13.3%) and for specimens collected most recently (2001-2004: 26.0%; 1999-2000: 12.6%). The age-adjusted rate of varicella seroprevalence for 1999-2004 was 93.6% for 6- to 19-year-olds and 98.0% for adults aged 20-49 years compared with 90.0% and 98.1%, respectively, for 1988-1994. We found an increase in seropositivity between the survey periods, from 93.2% to 97.2% (p < 0.001) among 12- to 19-year-olds. For children, non-Hispanic black ethnicity and younger age were associated with lower seroprevalence in both survey periods.

Conclusions: Varicella seroprevalence increased with age among children and was uniformly high in the U.S. adult population between 1999 and 2004. The original testing produced false-negative seroprevalence results among children's specimens collected between 1999 and 2004 from 6- to 19-year-olds.

Citing Articles

Computational design of prefusion-stabilized Herpesvirus gB trimers.

McCallum M, Veesler D bioRxiv. 2024; .

PMID: 39484573 PMC: 11526958. DOI: 10.1101/2024.10.23.619923.


Herpes zoster and long-term risk of subjective cognitive decline.

Yeh T, Curhan G, Yawn B, Willett W, Curhan S Alzheimers Res Ther. 2024; 16(1):180.

PMID: 39138535 PMC: 11323373. DOI: 10.1186/s13195-024-01511-x.


Intravenous Immunoglobulin and Intravenous Acyclovir as an Alternative Therapy to Varicella Zoster Immunoglobulin in the Prevention of Serious Complications of Neonatal Varicella.

Alhwayan A, Alsallal A, Njadat M, Alhammad M, Haddadin B Cureus. 2024; 16(6):e63515.

PMID: 39081426 PMC: 11288336. DOI: 10.7759/cureus.63515.


Primary Varicella Infection in a Young Adult from the Democratic Republic of the Congo: A Case Report and Mini-Review.

McNaughton A, Karsenti N, Kwan J, Adawi A, Mansuri S, Boggild A Infect Dis Rep. 2024; 16(4):628-637.

PMID: 39051248 PMC: 11270367. DOI: 10.3390/idr16040048.


Contribution of CNS and extra-CNS infections to neurodegeneration: a narrative review.

Kettunen P, Koistinaho J, Rolova T J Neuroinflammation. 2024; 21(1):152.

PMID: 38845026 PMC: 11157808. DOI: 10.1186/s12974-024-03139-y.


References
1.
Marin M, Guris D, Chaves S, Schmid S, Seward J . Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007; 56(RR-4):1-40. View

2.
Guris D, Jumaan A, Mascola L, Watson B, Zhang J, Chaves S . Changing varicella epidemiology in active surveillance sites--United States, 1995-2005. J Infect Dis. 2008; 197 Suppl 2:S71-5. DOI: 10.1086/522156. View

3.
. Prevention of varicella: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Centers for Disease Control and Prevention. MMWR Recomm Rep. 1996; 45(RR-11):1-36. View

4.
Maple P, Gray J, Breuer J, Kafatos G, Parker S, Brown D . Performance of a time-resolved fluorescence immunoassay for measuring varicella-zoster virus immunoglobulin G levels in adults and comparison with commercial enzyme immunoassays and Merck glycoprotein enzyme immunoassay. Clin Vaccine Immunol. 2006; 13(2):214-8. PMC: 1391932. DOI: 10.1128/CVI.13.2.214-218.2006. View

5.
Kilgore P, Kruszon-Moran D, Seward J, Jumaan A, Van Loon F, Forghani B . Varicella in Americans from NHANES III: implications for control through routine immunization. J Med Virol. 2003; 70 Suppl 1:S111-8. DOI: 10.1002/jmv.10364. View